In his first State of the Union speech, President Trump once again promised to lower the swelling costs of prescription drugs. The question is – will the administration do it without imposing price controls.

Sens. Chuck Grassley (R-Iowa) and Patrick Leahy (D-Vt.) reintroduced the CREATES Act, S. 974, in an effort to close regulatory loopholes at the Food and Drug Administration (FDA) that limit competition in the emerging market for biosimilars. Sen. Mike Lee and all of the other cosponsors of last year’s bill have returned as cosponsors. Rep. Tom Marino also introduced this bill in the House of Representatives on April 27th.